Choose the right treatment, at the right dose – a way to create a financially-sustainable cancer care?
Using treatments only where clear benefit has been demonstrated and modulating doses based on evidence are potentially effective strategies to reduce the rising costs of oncology
Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
Doublet immunotherapy consolidates its role in hepatocellular carcinoma
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Ten years of improvement in the treatment of liver cancer
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
Targeting KRAS offers new hope for patients with gastrointestinal cancers
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours
Towards a brighter future for gynaecological cancers
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
New insights into the evolutionary pattern of breast cancer
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Making personalised precision medicine a reality for early breast cancer
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices